vs
Side-by-side financial comparison of AbbVie (ABBV) and GE HealthCare (GEHC). Click either name above to swap in a different company.
AbbVie is the larger business by last-quarter revenue ($16.6B vs $5.7B, roughly 2.9× GE HealthCare). AbbVie runs the higher net margin — 10.9% vs 10.3%, a 0.6% gap on every dollar of revenue. On growth, AbbVie posted the faster year-over-year revenue change (10.0% vs 7.1%). Over the past eight quarters, AbbVie's revenue compounded faster (16.2% CAGR vs 10.7%).
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. They have produced drugs to treat a wide range of medical issues.
GE Healthcare Technologies, Inc., stylized GE HealthCare, is an American health technology company based in Chicago, Illinois. It operates four divisions: Medical imaging, which includes molecular imaging, computed tomography, magnetic resonance, women’s health screening and X-ray systems; Ultrasound; Patient Care Solutions, which is focused on remote patient monitoring, anesthesia and respiratory care, diagnostic cardiology, and infant care; and Pharmaceutical Diagnostics, which manufactures...
ABBV vs GEHC — Head-to-Head
Income Statement — Q4 2025 vs Q4 2025
| Metric | | |
|---|---|---|
| Revenue | $16.6B | $5.7B |
| Net Profit | $1.8B | $588.0M |
| Gross Margin | 72.6% | 39.7% |
| Operating Margin | 27.3% | 14.5% |
| Net Margin | 10.9% | 10.3% |
| Revenue YoY | 10.0% | 7.1% |
| Net Profit YoY | 8354.5% | -18.4% |
| EPS (diluted) | $1.02 | $1.28 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.6B | $5.7B | ||
| Q3 25 | $15.8B | $5.1B | ||
| Q2 25 | $15.4B | $5.0B | ||
| Q1 25 | $13.3B | $4.8B | ||
| Q4 24 | $15.1B | $5.3B | ||
| Q3 24 | $14.5B | $4.9B | ||
| Q2 24 | $14.5B | $4.8B | ||
| Q1 24 | $12.3B | $4.7B |
| Q4 25 | $1.8B | $588.0M | ||
| Q3 25 | $186.0M | $446.0M | ||
| Q2 25 | $938.0M | $486.0M | ||
| Q1 25 | $1.3B | $564.0M | ||
| Q4 24 | $-22.0M | $721.0M | ||
| Q3 24 | $1.6B | $470.0M | ||
| Q2 24 | $1.4B | $428.0M | ||
| Q1 24 | $1.4B | $374.0M |
| Q4 25 | 72.6% | 39.7% | ||
| Q3 25 | 66.4% | 38.7% | ||
| Q2 25 | 71.8% | 39.6% | ||
| Q1 25 | 70.0% | 42.1% | ||
| Q4 24 | 70.9% | 42.8% | ||
| Q3 24 | 70.9% | 41.7% | ||
| Q2 24 | 70.9% | 41.4% | ||
| Q1 24 | 66.7% | 40.9% |
| Q4 25 | 27.3% | 14.5% | ||
| Q3 25 | 12.1% | 12.7% | ||
| Q2 25 | 31.7% | 13.1% | ||
| Q1 25 | 28.0% | 13.2% | ||
| Q4 24 | -9.9% | 15.1% | ||
| Q3 24 | 26.5% | 13.9% | ||
| Q2 24 | 27.6% | 12.6% | ||
| Q1 24 | 22.7% | 11.6% |
| Q4 25 | 10.9% | 10.3% | ||
| Q3 25 | 1.2% | 8.7% | ||
| Q2 25 | 6.1% | 9.7% | ||
| Q1 25 | 9.6% | 11.8% | ||
| Q4 24 | -0.1% | 13.6% | ||
| Q3 24 | 10.8% | 9.7% | ||
| Q2 24 | 9.5% | 8.8% | ||
| Q1 24 | 11.1% | 8.0% |
| Q4 25 | $1.02 | $1.28 | ||
| Q3 25 | $0.10 | $0.98 | ||
| Q2 25 | $0.52 | $1.06 | ||
| Q1 25 | $0.72 | $1.23 | ||
| Q4 24 | $-0.03 | $1.58 | ||
| Q3 24 | $0.88 | $1.02 | ||
| Q2 24 | $0.77 | $0.93 | ||
| Q1 24 | $0.77 | $0.81 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $5.3B | $4.5B |
| Total DebtLower is stronger | $58.9B | $10.0B |
| Stockholders' EquityBook value | $-3.3B | $10.4B |
| Total Assets | $134.0B | $36.9B |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.3B | $4.5B | ||
| Q3 25 | $5.7B | $4.0B | ||
| Q2 25 | $6.5B | $3.7B | ||
| Q1 25 | $5.2B | $2.5B | ||
| Q4 24 | $5.6B | $2.9B | ||
| Q3 24 | $7.3B | $3.5B | ||
| Q2 24 | $13.2B | $2.0B | ||
| Q1 24 | $18.1B | $2.6B |
| Q4 25 | $58.9B | $10.0B | ||
| Q3 25 | $63.0B | $10.3B | ||
| Q2 25 | $63.0B | $10.3B | ||
| Q1 25 | $64.5B | $8.8B | ||
| Q4 24 | $60.3B | $9.0B | ||
| Q3 24 | $58.5B | $10.3B | ||
| Q2 24 | $58.0B | $9.2B | ||
| Q1 24 | $63.8B | $9.3B |
| Q4 25 | $-3.3B | $10.4B | ||
| Q3 25 | $-2.6B | $10.0B | ||
| Q2 25 | $-183.0M | $9.7B | ||
| Q1 25 | $1.4B | $9.2B | ||
| Q4 24 | $3.3B | $8.4B | ||
| Q3 24 | $6.0B | $8.3B | ||
| Q2 24 | $6.8B | $7.8B | ||
| Q1 24 | $8.0B | $7.4B |
| Q4 25 | $134.0B | $36.9B | ||
| Q3 25 | $133.9B | $36.1B | ||
| Q2 25 | $137.2B | $35.5B | ||
| Q1 25 | $136.2B | $33.6B | ||
| Q4 24 | $135.2B | $33.1B | ||
| Q3 24 | $143.4B | $33.9B | ||
| Q2 24 | $141.9B | $31.9B | ||
| Q1 24 | $148.9B | $32.2B |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 1.03× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | 45.44× | 0.95× | ||
| Q4 24 | 18.15× | 1.06× | ||
| Q3 24 | 9.70× | 1.24× | ||
| Q2 24 | 8.56× | 1.18× | ||
| Q1 24 | 7.97× | 1.25× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $5.2B | — |
| Free Cash FlowOCF − Capex | $4.9B | — |
| FCF MarginFCF / Revenue | 29.4% | — |
| Capex IntensityCapex / Revenue | 2.0% | 2.4% |
| Cash ConversionOCF / Net Profit | 2.87× | — |
| TTM Free Cash FlowTrailing 4 quarters | $17.8B | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $5.2B | — | ||
| Q3 25 | $7.0B | — | ||
| Q2 25 | $5.2B | $94.0M | ||
| Q1 25 | $1.6B | $250.0M | ||
| Q4 24 | $7.0B | — | ||
| Q3 24 | $5.4B | — | ||
| Q2 24 | $2.3B | $-119.0M | ||
| Q1 24 | $4.0B | $419.0M |
| Q4 25 | $4.9B | — | ||
| Q3 25 | $6.6B | — | ||
| Q2 25 | $4.9B | $8.0M | ||
| Q1 25 | $1.4B | $98.0M | ||
| Q4 24 | $6.8B | — | ||
| Q3 24 | $5.2B | — | ||
| Q2 24 | $2.0B | $-183.0M | ||
| Q1 24 | $3.8B | $274.0M |
| Q4 25 | 29.4% | — | ||
| Q3 25 | 42.1% | — | ||
| Q2 25 | 31.7% | 0.2% | ||
| Q1 25 | 10.5% | 2.1% | ||
| Q4 24 | 44.7% | — | ||
| Q3 24 | 35.9% | — | ||
| Q2 24 | 14.0% | -3.8% | ||
| Q1 24 | 31.3% | 5.9% |
| Q4 25 | 2.0% | 2.4% | ||
| Q3 25 | 2.4% | 2.1% | ||
| Q2 25 | 1.7% | 1.7% | ||
| Q1 25 | 1.8% | 3.2% | ||
| Q4 24 | 1.9% | 1.9% | ||
| Q3 24 | 1.7% | 1.9% | ||
| Q2 24 | 1.7% | 1.3% | ||
| Q1 24 | 1.6% | 3.1% |
| Q4 25 | 2.87× | — | ||
| Q3 25 | 37.76× | — | ||
| Q2 25 | 5.49× | 0.19× | ||
| Q1 25 | 1.27× | 0.44× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.49× | — | ||
| Q2 24 | 1.66× | -0.28× | ||
| Q1 24 | 2.95× | 1.12× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ABBV
Segment breakdown not available.
GEHC
| Imaging Segment | $2.6B | 45% |
| PCS Segment | $824.0M | 14% |
| P Dx Segment | $790.0M | 14% |
| Specialized Ultrasound Subsegment | $735.0M | 13% |
| Monitoring Solutions Subsegment | $578.0M | 10% |
| Life Support Solutions Subsegment | $247.0M | 4% |
